🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

LLS Visionaries of the Year 2023 on Bonfire bonfire.com/lls-visionarie…

How can you access personalized #Myeloma care and treatment? Hear advice from experts Ashley Rosko and Francesca Cottini of The James. buff.ly/3PrRMAY #MMsm

Excited to share our paper ! Hopefully the use of CAR T products expands in the future i Promises and challenges of a decentralized CAR T-cell manufacturing model frontiersin.org/articles/10.33… Marcos de Lima Evandro Bezerra Ohio State Hematology Ohio State Medical Oncology Hem-Onc Fellows Network

Pub Alert 🚨 Francesca Cottini and other members from the #MultipleMyeloma Team published “Impact of interval progression before autologous stem cell transplant in patients with multiple myeloma” in Frontiers - Oncology pubmed.ncbi.nlm.nih.gov/37554170/

Scientific workshop on Hematology and Aging ASH

Only at ASH central #ASH23 #mmsm

OncData had the pleasure of speaking with Dr. Evandro Bezerra (Evandro Bezerra) of Ohio State Hematology about his study "Real-World Outcomes of #BrexuCel for R/R B-Cell #ALL. Stay tuned to hear the podcast!

Who says Ohio State and University of Michigan can’t get along? Thanks for the teamwork, Dr. Ryan Wilcox and John Reneau John Reneau! The James U-M Rogel Cancer Center #ASH2023

More photos from our Big Ten CRC lymphoid, myeloid, BMT/SCT, and multiple myeloma #ASH2023 meetings today! Craig Emmitt Cole Chris Strouse Matthew Pianko, MD Natalie Callander John Reneau Francesca Cottini Timothy Schmidt, MD Attaya Suvannasankha Andrew M. Evens, DO, MBA, MSc

Starting soon! #ASH2023 #mmsm

Excellent The James Oncogeriatric Grand Rounds today by Megan Moore Weivoda 10% of skeleton bone is remodeled annually. Fascinated by 🦴 pits and trenches and relationship to #gerionc and senescence. Ohio State Hematology

#myeloma Happy to share the last work of our lab on the role of CD56 in predicting response to Dara-IMiDs in patients with myeloma. Thanks to my team, especially AJ Robinette Ohio State Hematology Ohio State WIMS Pelotonia

Pub Alert 🚨 Francesca Cottini, MD (Francesca Cottini) published "CD56 expression predicts response to Daratumumab-based regimens" in Blood Cancer Journal. nature.com/articles/s4140…

Excite and honored to be a part of AMPATH myeloma workshop in Eldoret, Kenya, to educate and mentor providers, engage with key stakeholders and advocacy groups to make bispecific antibodies available in Western Africa. #AMPATH #MoiUniversity #IUCancerCenter #IUSchoolMedicine

#Myeloma Paper of the Day: CREB1 promotes expression of immune checkpoint HLA-E, which binds to natural killer group 2A (NKG2A) inhibitory NK signal signal, leading to immune escape in multiple myeloma: pubmed.ncbi.nlm.nih.gov/38902472/.

Myeloma Paper of the Day, June 24th, suggested by Robert Z. Orlowski Francesca Cottini oncodaily.com/91214.html #Cancer #Myeloma #MyelomaPaperOfTheDay #OncoDaily #Oncology

🥼 Researchers led by Dr. Francesca Cottini at The Ohio State University College of Medicine identified non-classical major histocompatibility complex class I molecule HLA-E as a major contributing factor in #immune escape. 👓 Learn more at Leukemia Journal | go.nature.com/3RKzdIG

We're honored to announce that Francesca Cottini, MD, has earned the inaugural Mason Fisher Grant. The award, funded by Pelotonia, supports research of genetic mutations that can lead to cancer. cancer.osu.edu/blog/hematolog…

I spy a Francesca Cottini 4th from the right 👀🎉 Congrats to all the awardees, especially her! 🌟👏 #CareerDevelopment #InnovationInResearch